
  
    
      
        Background_NNP
        Loss_NN of_IN myocytes_NNS is_VBZ thought_VBN to_TO contribute_VB to_TO the_DT
        progressivedecline_NN in_IN left_JJ ventricular_NN function_NN and_CC the_DT
        development_NN of_IN congestiveheart_NN failure_NN ._. Recent_JJ studies_NNS have_VBP
        proposed_VBN that_DT myocyte_NN loss_NN incardiomyopathy_NN can_MD occur_VB by_IN
        apoptosis_NNS without_IN an_DT inflammatory_JJ response_NN [_NN reviewedin_NN [_NN 1_CD
        2_CD 3_CD ]_NN ]_NN ._. In_IN heart_NN failure_NN ,_, growth_NN stimulation_NN initially_RB
        occurs_VBZ as_IN a_DT compensatory_JJ effort_NN tomeet_NN chronically_RB altered_VBD
        hemodynamic_JJ demands_NNS and_CC is_VBZ mediated_JJ by_IN systemicand_NN /_NN or_CC local_JJ
        up-regulation_JJ of_IN mediators_NNS of_IN adrenergic_JJ pathways_NNS andby_NN
        various_JJ cytokines_NNS [_NN 4_CD 5_CD ]_NN ._. However_RB ,_, cytokinescan_NN be_VB
        directly_RB toxic_JJ to_TO cardiac_JJ myocytes_NNS and_CC result_NN in_IN
        increasedapoptotic_JJ cell_NN death_NN [_NN 3_CD 6_CD ]_NN ._. Local_JJ
        up-regulationof_JJ angiotensin_NN II_NNP induces_VBZ immediate-early_JJ
        genes_NNS ,_, which_WDT may_MD leadto_NN increased_VBD protein_NN synthesis_NN and_CC
        myocardial_NN hypertrophy_NN or_CC ,_, alternatively_RB ,_, may_MD up-regulate_JJ
        expression_NN of_IN apoptotic_JJ proteins_NNS (_( such_JJ as_IN p_NN 53_CD )_) incardiac_NN
        myocytes_NNS ._. The_DT initial_JJ increase_NN in_IN circulating_VBG
        norepinephrineis_NNS thought_VBD to_TO maintain_VB cardiac_JJ function_NN
        through_IN inotropic_JJ mechanisms_NNS ._. However_RB ,_, a_DT direct_JJ cardiac_JJ
        myocyte_NN toxicity_NN from_IN norepinephrine_NN iswell_NN recognized_VBD [_NN 6_CD
        7_CD ]_NN ._. Furthermore_RB ,_, pressure-overloadand_JJ stretch_NN associated_VBN
        release_NN of_IN angiotensin_NN II_NNP has_VBZ been_VBN shownto_NN induce_VB myocyte_NN
        apoptosis_NNS [_NN 8_CD 9_CD 10_CD ]_NN ._. In_IN an_DT elegant_JJ paper_NN by_IN Telger_NNP et_CC al_NN ._. ,_,
        it_PRP has_VBZ clearly_RB been_VBN demonstratedthat_NN cardiac_JJ hypertrophy_NN is_VBZ
        initially_RB preceded_VBN by_IN a_DT wave_NN of_IN apoptosisof_NN cardiac_JJ
        myocytes_NNS followed_VBN by_IN cell_NN growth_NN and_CC a_DT decrease_NN in_IN
        programmedcell_NN death_NN [_NN 10_CD ]_NN ._. Apoptosis_NNP may_MD ,_, therefore_RB ,_, be_VBP
        the_DT consequence_NN of_IN prolonged_JJ growth_NN stimulation_NN
        (_( adrenergicand_NN renin-angiotensin_JJ axes_NNS )_) of_IN adult_NN cardiac_JJ
        myocytes_NNS ,_, which_WDT areterminally_RB differentiated_JJ ._. Similarly_RB ,_,
        certain_JJ cytokines_NNS (_( such_JJ astumor_NN necrosis_NNS factor_NN )_) can_MD induce_VB
        growth_NN as_RB well_RB as_IN apoptosis_NNS [_NN 11_CD ]_NN ._. As_IN proposed_VBN by_IN Telger_NNP
        et_CC al_NN ._. it_PRP isbecoming_VBG clear_JJ that_DT cell_NN growth_NN and_CC programmed_VBN
        cell_NN death_NN are_VBP infact_NN two_CD linked_VBN processes_VBZ [_NN 10_CD ]_NN ._.
        Over_IN the_DT last_JJ five_CD years_NNS ,_, β-blocker_JJ therapy_NN has_VBZ become_VBN
        one_CD ofthe_NN main_JJ treatment_NN modalities_NNS for_IN heart_NN failure_NN ._. Of_IN
        particular_JJ interestis_NNS the_DT use_NN of_IN carvedilol_NN [_NN 12_CD 13_CD 14_CD 15_CD
        16_CD ]_NN ._. Carvedilol_NNP is_VBZ a_DT novel_NN multiple-action_JJ neurohormonal_NN
        antagonist_NN ._. Its_PRP$ primary_JJ activities_NNS are_VBP nonselective_JJ
        β-adrenoceptor_JJ blockade_NN ,_, vasodilatation_NN (_( mediated_JJ through_IN
        α_NN 1_CD -_: adrenoceptor_NN blockade_NN )_) ,_, andantioxidant_NN activity_NN [_NN 12_CD ]_NN ._.
        In_IN many_JJ clinical_JJ studies_NNS ,_, carvedilol_NN has_VBZ been_VBN shown_VBN to_TO
        improve_VB left_VBD ventricular_NN function_NN andsymptoms_NNS in_IN patients_NNS
        with_IN ischemic_JJ heart_NN disease_NN or_CC idiopathic_JJ
        dilatedcardiomyopathy_NN [_NN 13_CD 14_CD 15_CD 16_CD ]_NN andto_NN dramatically_RB
        reduce_VB mortality_NN [_NN 17_CD ]_NN ._. However_RB ,_, it_PRP remains_VBZ unclear_JJ how_WRB
        carvedilol_NN improves_VBZ ventricular_NN functionin_NN heart_NN
        failure_NN ._.
        In_IN an_DT animal_NN model_NN of_IN cardiomyopathy_NN that_WDT has_VBZ many_JJ
        similaritiesto_NN human_JJ heart_NN failure_NN ,_, we_PRP tested_VBD the_DT
        hypothesis_NNS that_IN a_DT reductionin_NN apoptosis_NNS may_MD be_VB responsible_JJ
        for_IN the_DT beneficial_JJ effects_NNS of_IN carvedilol_NN ._. As_IN such_JJ ,_,
        attenuation_NN of_IN apoptosis_NNS in_IN the_DT myocardium_NN may_MD representa_NN
        novel_NN and_CC important_JJ mechanism_NN that_WDT contributes_VBZ beneficial_JJ
        effects_NNS onthe_NN myocardium_NN ._.
      
      
        Results_NNS
        
          Baseline_NNP Characteristics_NNP of_IN Dilated_NNP Cardiomyopathic_NNP
          Animals_NNPS
          We_PRP have_VBP previously_RB shown_VBN that_DT removal_NN of_IN furazolidone_NN
          from_IN thefeed_JJ after_IN three_CD weeks_NNS results_NNS in_IN progressive_JJ
          cardiac_JJ dilatationand_NN heart_NN failure_NN [_NN 18_CD ]_NN ._. At_IN the_DT time_NN
          ofrandomization_NN of_IN the_DT DCM_NNP group_NN into_IN three_CD groups_NNS i_NNP ._. e_SYM ._. ,_,
          DCM_NNP 
          0_CD (_( notreatment_NN )_) ,_, DCM_NNP 
          1_CD (_( lower_JJR dose_NN carvedilol_NN )_) or_CC DCM_NNP 
          20_CD (_( higherdose_NN carvedilol_NN )_) ,_, fractional_JJ
          shortening_NN was_VBD not_RB different_JJ betweenthe_NN groups_NNS (_( p_NN >_NN
          0_CD ._. 1_LS )_) ._. Evidence_NN for_IN severe_JJ heart_NN failure_NN was_VBD markedby_NN
          significantly_RB reduced_VBD left_VBD ventricle_NN fractional_JJ
          shortening_NN (_( controls_NNS 63_CD ._. 67_CD ±_NN 1_CD ._. 04_CD %_NN n_NN =_SYM 34_CD vs_NNS ._. DCM_NNP 11_CD ._. 95_CD ±_NN
          0_CD ._. 59_CD %_NN n_NN =_SYM 18_CD ,_, p_NN <_NN 0_CD ._. 001_CD )_) ._.
        
        
          Effect_NN of_IN Carvedilol_NNP on_IN Ventricular_NNP Function_NNP
          We_PRP investigated_VBD the_DT effect_NN of_IN carvedilol_NN by_IN
          administering_VBG twodifferent_NN dosages_NNS (_( 1_CD mg_NN and_CC 20_CD mg_NN /_NN kg_NN
          body_NN weight_NN per_IN day_NN )_) to_TO controland_NN DCM_NNP turkeys_NNS for_IN four_CD
          weeks_NNS ._. We_PRP studied_VBD two_CD dosages_NNS (_( pharmacologicaland_NN
          non-pharmacological_JJ )_) as_IN a_DT difference_NN in_IN dose-dependency_JJ
          forcardiac_NN function_NN improvement_NN has_VBZ previously_RB been_VBN
          demonstrated_VBN byus_JJ with_IN another_DT non-selective_JJ beta-blocker_NN
          [_NN 18_CD ]_NN ._. Furthermore_RB ,_, we_PRP wanted_VBD to_TO determine_VB if_IN carvedilol_NN
          might_MD exert_VB beneficialeffects_NNS independent_JJ of_IN heart_NN rate_NN
          effects_NNS ._. The_DT lower_JJR dose_NN (_( 1_CD mg_NN /_NN kg_NN )_) did_VBD not_RB reduce_VB heart_NN
          rate_NN ._. However_RB ,_, the_DT higher_JJR dose_NN reduced_VBD HR_NNP byapproximately_RB
          15_CD %_NN for_IN 8_CD hours_NNS ._.
          
          In_IN vivo_NN contractile_NN performance_NN of_IN
          the_DT heart_NN was_VBD assessed_VBN bythe_NN determination_NN of_IN fractional_JJ
          shortening_NN of_IN the_DT left_NN ventricle_NN ._. As_IN shown_VBN in_IN Table_NNP 1_CD and_CC
          Figure_NN 1_CD ,_, fractional_JJ shortening_NN was_VBD increasedby_NN 32_CD and_CC
          45_CD %_NN in_IN DCM_NNP 
          1_CD and_CC DCM_NNP 
          20_CD animals_NNS ,_, respectively_RB ,_, compared_VBN to_TO
          non-treated_JJ DCM_NNP animals_NNS (_( DCM_NNP 
          0_CD )_) ._. Comparedwith_NNP baseline_NN values_NNS at_IN
          the_DT time_NN of_IN randomization_NN ,_, the_DT improvementin_NN fractional_JJ
          shortening_NN was_VBD of_IN 57_CD %_NN in_IN DCM_NNP 
          1_CD and_CC 65_CD %_NN inDCM_NN 
          20_CD ._. Associated_NNP with_IN improved_VBN cardiac_JJ
          function_NN wasa_NN reduction_NN in_IN the_DT incidence_NN of_IN apoptotic_JJ
          nuclei_NN (_( see_VB below_IN )_) ._.
          The_DT body_NN weight_NN was_VBD significantly_RB decreased_VBN in_IN DCM_NNP
          animals_NNS comparedto_NN control_NN animals_NNS (_( p_NN <_NN 0_CD ._. 001_CD compared_VBN
          to_TO control_VB )_) (_( Table_NNP 2_LS )_) ._. This_DT animal_NN model_NN is_VBZ associated_VBN
          withcachexia_NN ._. Carvedilol_NNP treatment_NN resulted_VBD in_IN a_DT slight_JJ
          gain_NN of_IN bodyweight_NN ,_, 15_CD %_NN in_IN the_DT DCM_NNP 
          1_CD group_NN and_CC 20_CD %_NN in_IN the_DT DCM_NNP 
          20_CD groupcompared_JJ with_IN the_DT non-treated_JJ
          DCM_NNP group_NN (_( DCM_NNP 
          0_CD )_) ._. Carvediloalso_NNP increased_VBD the_DT body_NN
          weight_NN of_IN control_NN animals_NNS (_( p_NN <_NN 0_CD ._. 001_CD )_) ._. These_DT data_NNS
          indicate_VBP a_DT favorable_JJ effect_NN on_IN cachexia_NN ._. In_IN
          non-treated_JJ DCM_NNP animals_NNS the_DT hearts_NNS weighed_VBD significantly_RB
          less_JJR than_IN control_NN hearts_NNS (_( p_NN =_SYM 0_CD ._. 01_CD )_) ._. DCM_NNP animals_NNS treated_VBN
          with_IN carvedilol_NN showed_VBD a_DT significantincrease_NN in_IN HW_NNP
          compared_VBD to_TO hearts_NNS from_IN non-treated_JJ DCM_NNP animals_NNS (_( p_NN <_NN
          0_CD ._. 001_CD )_) ._. Therefore_RB the_DT HW_NNP /_NN BW_NNP ratio_NN was_VBD lower_JJR for_IN hearts_NNS
          fromcarvedilol_NN treated_VBD DCM_NNP animals_NNS compared_VBN to_TO hearts_NNS
          from_IN non-treated_JJ DCM_NNP animals_NNS ._. Interestingly_RB ,_, the_DT HW_NNP /_NN BW_NNP
          ratio_NN was_VBD lower_JJR for_IN carvediloltreated_JJ control_NN animals_NNS
          compared_VBN to_TO non-treated_JJ control_NN animals_NNS ._. Left_NNP ventricle_NN
          volume_NN was_VBD significantly_RB larger_JJR for_IN non-treated_JJ
          DCMhearts_NNP ._. Carvedilol_NNP significantly_RB decreased_VBD LV_NNP volume_NN
          at_IN both_DT dosages_NNS ._.
        
        
          Effect_NN of_IN Carvedilol_NNP on_IN Cardiac_NNP Myocyte_NNP
          Apoptosis_NNP
          Evaluation_NNP of_IN tissue_NN sections_NNS by_IN the_DT TUNEL_NNP technique_NN
          revealedonly_RB small_JJ numbers_NNS of_IN TUNEL-positive_NNP cells_NNS in_IN the_DT
          control_NN hearts_NNS (_( Table_NNP 1_CD and_CC Figure_NN 2_CD A_DT )_) ._. Hearts_NNPS from_IN
          DCManimals_NNP had_VBD a_DT significant_JJ increase_NN in_IN the_DT number_NN of_IN
          TUNEL-positivecells_NNP compared_VBD to_TO controls_NNS (_( 5_CD ._. 64_CD ±_NN 0_CD ._. 49_CD %_NN
          vs_NNS ._. 1_CD ._. 72_CD ±_NN 0_CD ._. 12_CD %_NN DCM_NNP andcontrol_NN respectively_RB ,_, p_NN <_NN
          0_CD ._. 001_CD )_) ,_, indicating_VBG the_DT occurrence_NN ofapoptosis_NNS (_( Figure_NN
          2_CD B_NNP )_) ._.
          In_IN contrast_NN to_TO non-treated_JJ DCM_NNP hearts_NNS ,_, myocardial_NN
          tissue_NN sectionsprepared_JJ from_IN hearts_NNS from_IN animals_NNS treated_VBN
          with_IN carvedilol_NN showeda_NN significant_JJ reduction_NN in_IN the_DT
          numbers_NNS of_IN TUNEL-positive_NNP myocytenuclei_NN ._. An_DT example_NN of_IN
          such_JJ an_DT observation_NN is_VBZ depicted_VBN in_IN Figure_NN 3_CD Aand_NNP 3_CD B_NNP (_( DCM_NNP 
          1_CD and_CC DCM_NNP 
          20_CD respectively_RB )_) ._. Both_DT the_DT lower_JJR and_CC
          the_DT higher_JJR doses_NNS of_IN carvedilol_NN were_VBD effectivein_NN reducing_VBG
          apoptosis_NNS from_IN 5_CD ._. 64_CD ±_NN 0_CD ._. 49_CD %_NN in_IN non-treated_JJ DCM_NNP animalsto_NN
          almost_RB control_NN levels_NNS 2_CD ._. 32_CD ±_NN 0_CD ._. 23_CD %_NN (_( DCM_NNP 
          1_LS )_) and_CC 2_CD ._. 36_CD ±_NN 0_CD ._. 26_CD %_NN (_( DCM_NNP 
          20_CD )_) ,_, p_NN <_NN 0_CD ._. 001_CD ,_, compared_VBN to_TO DCM_NNP 
          0_CD respectively_RB (_( Figure_NN 3_CD C_NNP )_) ._.
        
      
      
        Discussion_NNP
        
          Effect_NN of_IN Carvedilol_NNP on_IN a_DT Heart_NNP Failure_NN
          Model_NNP
          The_DT furazolidone-induced_JJ turkey_NN model_NN is_VBZ a_DT well_JJ
          characterizedexperimental_NN model_NN of_IN dilated_JJ cardiomyopathy_NN
          with_IN features_NNS verysimilar_NN to_TO those_DT found_VBD in_IN human_JJ heart_NN
          failure_NN [_NN 19_CD 20_CD 21_CD 22_CD ]_NN ._. Decreased_NNP contractile_NN function_NN
          (_( reduced_VBN fractional_JJ shortening_NN ofthe_NN left_VBD ventricle_NN )_) and_CC
          morphological_JJ changes_NNS (_( increased_VBN heart_NN volumes_NNS ,_, left_VBD
          ventricular_NN dilatation_NN ,_, and_CC myocyte_NN hypertrophy_NN )_) are_VBP
          characteristic_JJ featuresof_NN this_DT model_NN [_NN 21_CD 22_CD ]_NN ._.
          β-blocker_JJ treatment_NN has_VBZ emerged_VBN as_IN an_DT effective_JJ
          treatment_NN modalityfor_NN heart_NN failure_NN ._. Both_DT in_IN animal_NN and_CC
          human_JJ studies_NNS of_IN heart_NN failure_NN ,_, β-adrenergicblockade_JJ
          intervention_NN appears_VBZ to_TO have_VB beneficial_JJ effects_NNS on_IN
          cardiacmyocyte_NN function_NN [_NN 1_CD 23_CD 24_CD ]_NN ._. Of_IN
          particularimportance_NN ,_, studies_NNS using_VBG carvedilol_NN have_VBP shown_VBN
          remarkable_JJ improvementsin_NN cardiac_JJ performance_NN [_NN 12_CD 13_CD 15_CD
          16_CD ]_NN andreduction_NN in_IN mortality_NN in_IN humans_NNS [_NN 17_CD ]_NN ._. We_PRP have_VBP
          previously_RB shown_VBN that_DT propranolol_NN ,_, a_DT nonselective_JJ
          β-blocker_JJ ,_, is_VBZ cardioprotective_JJ and_CC prevents_VBZ the_DT
          development_NN of_IN heart_NN failurein_NN turkeys_NNS when_WRB given_VBN
          concurrently_RB with_IN furazolidone_NN [_NN 21_CD ]_NN ._. Similarly_RB ,_,
          carteolol_NN ,_, a_DT nonselective_JJ β-blocker_JJ ,_, resulted_VBD in_IN
          improvement_NN in_IN ejection_NN fraction_NN ,_, reduction_NN in_IN
          ventricularvolumes_NNS ,_, an_DT increase_NN in_IN developed_VBN pressure_NN as_RB
          well_RB as_IN an_DT increasein_NN rate_NN of_IN survival_NN in_IN our_PRP$ turkey_NN
          model_NN [_NN 18_CD ]_NN ._. Improvementin_NNP cardiac_JJ function_NN was_VBD
          associated_VBN with_IN cellular_JJ remodeling_NN of_IN cardiacmyocytes_NNS ._.
          Cardiac_NNP myocytes_NNS from_IN hearts_NNS treated_VBN with_IN a_DT non-selective_JJ
          β-blockeri_JJ ._. e_SYM ._. ,_, carteolol_NN ,_, had_VBD normal_JJ calcium_NN cycling_NN ,_,
          normal_JJ myocardial_NN energetics_NNS ,_, normal_JJ β_NN 
          1_CD receptor_NN density_NN as_RB well_RB as_IN
          regression_NN of_IN myocytehypertrophy_NN and_CC reduced_VBN connective_JJ
          tissue_NN content_NN [_NN 18_CD ]_NN ._. Furthermore_RB ,_, administration_NN of_IN
          carteolol_NN hasbeen_NN reported_VBD to_TO prevent_VB the_DT development_NN of_IN
          virally_RB induced_VBN cardiomyopathyin_NN a_DT murine_NN model_NN [_NN 25_CD ]_NN ._.
          In_IN a_DT canine_JJ modelwith_NN left_VBD ventricular_NN dysfunction_NN
          produced_VBN by_IN multiple_JJ sequentialintracoronary_JJ
          microembolizations_NNS ,_, long_JJ term_NN treatment_NN with_IN metoprolol_NN ,_, a_DT
          β_NN 
          1_CD -_: selective_JJ blocker_NN ,_, has_VBZ been_VBN
          reported_VBN to_TO preventthe_NN progression_NN of_IN LV_NNP systolic_JJ
          dysfunction_NN and_CC LV_NNP chamber_NN dilatation_NN [_NN 26_CD ]_NN ._. Similarly_RB ,_,
          our_PRP$ present_JJ findings_NNS onthe_NN effect_NN of_IN carvedilol_NN indicated_VBD
          improvement_NN of_IN left_JJ ventricularfunction_NN and_CC smaller_JJR LV_NNP
          volumes_NNS ._. Carvedilol_NNP prevented_VBD progressionof_NN LV_NNP systolic_JJ
          dysfunction_NN and_CC LV_NNP dilatation_NN as_RB previously_RB reportedin_NN
          other_JJ models_NNS using_VBG β-blockers_JJ [_NN 18_CD 26_CD ]_NN ._.
          Animals_NNS with_IN dilated_JJ cardiomyopathy_NN which_WDT received_VBD
          carvedilolshowed_JJ significant_JJ improvement_NN in_IN LV_NNP systolic_JJ
          function_NN after_IN 4_CD weeks_NNS ._. Notably_RB ,_, the_DT improvement_NN of_IN LV_NNP
          systolic_JJ function_NN in_IN animals_NNS treatedwith_NN carvedilol_NN was_VBD
          associated_VBN with_IN a_DT decrease_NN of_IN LV_NNP volumes_NNS comparedwith_NN
          non-treated_JJ DCM_NNP animals_NNS ._. Importantly_NNP ,_, both_DT doses_NNS of_IN
          carvedilolimproved_JJ LV_NNP contractile_NN performance_NN ._. Fractional_NNP
          shortening_VBG (_( %_NN )_) wasincreased_JJ by_IN an_DT average_NN of_IN
          approximately_RB 38_CD %_NN and_CC impressively_RB by_IN 80_CD %_NN in_IN some_DT
          individual_JJ animals_NNS ._. These_DT data_NNS seem_VBP to_TO agree_VB with_IN the_DT
          resultsof_NN human_JJ clinical_JJ studies_NNS ,_, and_CC are_VBP suggestive_JJ that_DT
          carvedilol_NN notonly_RB slows_VBZ deterioration_NN of_IN cardiac_JJ
          function_NN ,_, but_CC also_RB improvescardiac_NN function_NN ._.
          The_DT trend_NN that_IN the_DT 20_CD mg_NN /_NN kg_NN body_NN weight_NN dose_NN might_MD not_RB
          have_VB beenwell_NN tolerated_JJ was_VBD demonstrated_VBN by_IN some_DT animals_NNS
          becoming_VBG moribundfor_NN a_DT short_JJ period_NN after_IN dosing_VBG which_WDT
          might_MD be_VB due_JJ to_TO a_DT reductionin_NN heart_NN rate_NN and_CC cardiac_JJ
          output_NN with_IN resultant_JJ reflect_VB tachycardia_NN ._. We_PRP have_VBP
          previously_RB shown_VBN a_DT negative_JJ force-interval_JJ relationship_NN
          (_( i_NNP ._. e_SYM ._. ,_, negative_JJ treppe_NN )_) in_IN failing_VBG hearts_NNS with_IN this_DT model_NN
          [_NN 18_CD ]_NN ._. This_DT is_VBZ in_IN line_NN with_IN data_NNS from_IN humanstudies_NNS ,_,
          which_WDT showed_VBD that_IN when_WRB first_RB administered_VBN ,_, β-blockers_JJ
          actually_RB slowheart_NN rate_NN and_CC diminish_VB ejection_NN fraction_NN [_NN
          27_CD ]_NN ._. The_DT higher_JJR dose_NN of_IN carvedilol_NN significantly_RB reduced_VBD
          heart_NN rate_NN andblood_NN pressure_NN for_IN up_IN to_TO eight_CD hours_NNS ._.
          Animals_NNS that_IN tolerated_JJ thehigher_NN dose_NN did_VBD nevertheless_RB
          benefit_NN from_IN the_DT treatment_NN ._. This_DT issimilar_NN to_TO human_JJ
          clinical_JJ studies_NNS where_WRB greater_JJR benefit_NN is_VBZ derivedfrom_NN
          higher_JJR dosages_NNS ,_, if_IN tolerated_JJ [_NN 28_CD ]_NN ._.
        
        
          Apoptosis_NNP in_IN Animal_NNP Models_NNP of_IN Heart_NNP Failure_NN
          Heart_NNP failure_NN is_VBZ characterized_VBN by_IN progressive_JJ
          deterioration_NN ofglobal_NN left_VBD ventricular_NN function_NN over_IN
          time_NN ._. The_DT mechanisms_NNS responsiblefor_NN the_DT worsening_NN of_IN
          cardiac_JJ function_NN are_VBP not_RB clear_JJ ._. Loss_NN of_IN cardiacmyocytes_NNS
          has_VBZ been_VBN suspected_VBN to_TO be_VB a_DT feature_NN of_IN the_DT
          cardiomyopathicprocess_NNS that_WDT contributes_VBZ to_TO progressive_JJ
          decline_NN in_IN left_JJ ventricularfunction_NN and_CC the_DT development_NN
          of_IN congestive_JJ heart_NN failure_NN [_NN 29_CD ]_NN ._. Evidence_NN supporting_VBG
          the_DT concept_NN ofmyocyte_NN apoptosis_NNS occurrence_NN and_CC
          contribution_NN in_IN the_DT progressionof_NN heart_NN failure_NN has_VBZ been_VBN
          obtained_VBN from_IN a_DT variety_NN of_IN observations_NNS ,_, including_VBG 
          in_IN vitro_NN studies_NNS ,_, experimental_JJ
          animal_NN modelsof_NN cardiac_JJ dysfunction_NN ,_, and_CC studies_NNS on_IN
          cardiac_JJ tissue_NN obtainedfrom_NN patients_NNS with_IN end-stage_JJ heart_NN
          failure_NN [_NN 5_CD 7_CD 8_CD 9_CD 29_CD ]_NN ._.
          We_PRP sought_VBD to_TO evaluate_VB the_DT incidence_NN and_CC the_DT extent_NN of_IN
          apoptosisin_NN our_PRP$ animal_NN model_NN of_IN heart_NN failure_NN ._. Using_VBG the_DT
          TUNEL_NNP techniqueas_NNS a_DT means_NN of_IN detection_NN ,_, we_PRP were_VBD able_JJ to_TO
          document_VB the_DT occurrenceof_NN apoptosis_NNS in_IN ventricles_NNS from_IN
          failing_VBG hearts_NNS ,_, which_WDT was_VBD characterizedby_NN a_DT higher_JJR
          percentage_NN of_IN apoptotic_JJ nuclei_NN when_WRB compared_VBN to_TO controls_NNS
          (_( 5_CD ._. 64_CD %_NN vs_NNS ._. 1_LS ._. 72_CD %_NN )_) ._. These_DT apoptotic_JJ indexes_NNS are_VBP within_IN the_DT
          range_NN of_IN valuesin_NN heart_NN failure_NN reported_VBD in_IN the_DT
          literature_NN (_( 0_CD ._. 2_LS %_NN to_TO 35_CD %_NN )_) [_NN 3_CD 30_CD 31_CD 32_CD 33_CD ]_NN ._. The_DT high_JJ
          degreeof_NN variability_NN reported_VBD in_IN the_DT literature_NN in_IN the_DT
          magnitude_NN of_IN apoptosis_NNS maybe_RB due_JJ to_TO the_DT diversity_NN and_CC
          specificity_NN of_IN methods_NNS used_VBN to_TO quantifyapoptotic_JJ
          nuclei_NN ._.
          When_WRB reporting_VBG apoptotic_JJ nuclei_NN using_VBG the_DT TUNEL_NNP assay_NN ,_,
          two_CD observationsshould_NN be_VB considered_VBN ;_: 1_LS )_) although_IN
          apoptosis_NNS occurred_VBD in_IN our_PRP$ modelof_NN heart_NN failure_NN ,_, we_PRP might_MD
          have_VB missed_VBN ,_, in_IN random_JJ histologicalsections_NNS ,_, evidence_NN of_IN
          apoptosis_NNS thereby_RB under_IN estimating_VBG the_DT severityof_NN
          programmed_VBN cell_NN death_NN due_JJ to_TO the_DT fact_NN that_IN apoptotic_JJ
          cells_NNS undergorapid_NN phagocytosis_NNS with_IN the_DT entire_JJ process_NN
          lasting_JJ less_JJR than_IN twohours_NNS in_IN some_DT cell_NN systems_NNS [_NN 34_CD ]_NN ,_,
          and_CC 2_LS )_) apoptosisin_NN the_DT present_JJ study_NN was_VBD evaluated_VBN at_IN a_DT
          single_JJ time_NN point_NN when_WRB theheart_NN was_VBD still_RB undergoing_VBG LV_NNP
          remodeling_VBG ._. Hence_RB ,_, the_DT documentationof_NN apoptosis_NNS at_IN this_DT
          stage_NN may_MD not_RB reflect_VB the_DT true_JJ magnitude_NN ofits_NNS occurrence_NN
          during_IN the_DT initiation_NN and_CC transition_NN to_TO heart_NN failure_NN ._. In_IN
          a_DT rat_NN model_NN of_IN pressure-overload_JJ hypertrophy_NN produced_VBN by_IN
          aorticbanding_VBG ,_, apoptosis_NNS appeared_VBD to_TO peak_VB at_IN four_CD days_NNS
          and_CC gradually_RB subsidedafter_NN one_CD month_NN of_IN aortic_JJ banding_VBG [_NN
          9_CD ]_NN ._. Therefore_RB ,_, a_DT longitudinal_NN study_NN of_IN apoptosis_NNS in_IN
          failing_VBG hearts_NNS frominitiation_NN to_TO transition_NN to_TO failure_NN is_VBZ
          worth_JJ pursuing_NN ._. In_IN this_DT way_NN ,_, the_DT incidence_NN of_IN apoptosis_NNS
          can_MD be_VB documented_VBN as_IN the_DT heart_NN movesprogressively_RB from_IN
          normal_JJ to_TO compensated_VBN hypertrophy_NN and_CC finallyto_NN overt_JJ
          decompensated_JJ heart_NN failure_NN ._. These_DT animals_NNS were_VBD in_IN
          compensated_VBN heartfailure_NN and_CC ,_, often_RB in_IN the_DT non-treated_JJ
          group_NN ,_, went_VBD into_IN decompensatedheart_NN failure_NN when_WRB stressed_VBD
          during_IN echocardiographic_JJ examination_NN ._.
          With_IN improved_VBN cardiac_JJ function_NN ,_, there_EX should_MD be_VB a_DT
          reduction_NN inactivation_NN of_IN the_DT
          adrenergic-renin-angiotensin_JJ axes_NNS as_RB well_RB as_IN adecrease_NN in_IN
          activated_VBN cytokines_NNS such_JJ as_IN tumor-necrosis_JJ factor-α_JJ ._. In_IN
          our_PRP$ model_NN of_IN heart_NN failure_NN ,_, cardiac_JJ function_NN correlated_JJ
          withthe_NN incidence_NN of_IN apoptosis_NNS ._. As_IN described_VBD in_IN Table_NNP
          1_CD and_CC Figure_NN 3_CD ,_, there_EX were_VBD a_DT higher_JJR number_NN of_IN apoptotic_JJ
          cells_NNS in_IN hearts_NNS with_IN a_DT reductionin_NN fractional_JJ shortening_NN ._.
          In_IN contrast_NN ,_, control_NN hearts_NNS with_IN normalventricular_NN
          function_NN showed_VBD low_JJ rates_NNS of_IN apoptosis_NNS ._. The_DT extent_NN
          andoccurrence_NN of_IN apoptosis_NNS may_MD partially_RB explain_VB the_DT lack_NN
          of_IN an_DT overallincrease_NN in_IN heart_NN weight_NN in_IN hearts_NNS from_IN
          non-treated_JJ DCM_NNP animals_NNS ,_, despite_IN a_DT pronounced_VBN increase_NN in_IN
          heart_NN size_NN ._. These_DT observations_NNS ,_, and_CC the_DT results_NNS from_IN
          several_JJ animal_NN models_NNS ,_, demonstrate_VB that_IN apoptoticcells_NNS
          are_VBP present_JJ in_IN failing_VBG hearts_NNS ,_, suggesting_VBG that_IN apoptosis_NNS
          mightbe_NN a_DT mechanism_NN involved_VBD ,_, at_IN least_JJS in_IN part_NN ,_, in_IN the_DT
          progression_NN ofheart_NN failure_NN and_CC the_DT reduction_NN of_IN myocyte_NN
          mass_NN ._.
        
        
          Carvedilol_NNP Inhibition_NNP of_IN Apoptosis_NNP and_CC Improvement_NNP
          of_IN VentricularFunction_NNP
          The_DT extent_NN of_IN apoptosis_NNS in_IN cardiomyopathic_JJ animals_NNS was_VBD
          significantlyreduced_JJ by_IN treatment_NN with_IN carvedilol_NN ._. Both_DT
          the_DT lower_JJR and_CC higherdoses_NNS of_IN carvedilol_NN were_VBD effective_JJ in_IN
          decreasing_VBG the_DT rate_NN of_IN apoptosis_NNS (_( approximately_RB a_DT 58_CD %_NN
          reduction_NN )_) ._. This_DT observation_NN represents_VBZ animportant_NN
          finding_VBG in_IN demonstrating_VBG the_DT effectiveness_NN of_IN a_DT
          cardiovasculardrug_NN to_TO protect_VB against_IN continual_JJ cardiac_JJ
          myocyte_NN apoptosis_NNS in_IN failinghearts_NNS 
          in_IN vivo_NN ._. Furthermore_RB ,_, the_DT
          inhibition_NN of_IN apoptosisby_NN carvedilol_NN was_VBD accompanied_VBN by_IN
          signs_NNS of_IN improvement_NN in_IN left_JJ ventricularfunction_NN and_CC
          heart_NN size_NN (_( i_NNP ._. e_SYM ._. reduced_VBN LV_NNP volume_NN )_) in_IN the_DT
          myopathicanimals_NNS ._. Whether_IN the_DT improved_VBN function_NN ,_, small_JJ
          heart_NN size_NN and_CC decreasedwall_NN stress_NN were_VBD responsible_JJ for_IN
          a_DT reduction_NN in_IN apoptosis_NNS is_VBZ notknown_NN ._. However_RB ,_, the_DT
          derived_VBN cardiac_JJ benefit_NN was_VBD independent_JJ of_IN heartrate_NN
          effects_NNS because_IN benefit_NN was_VBD obtained_VBN at_IN both_DT dosages_NNS ._.
          Our_PRP$ data_NNS support_VBP the_DT conclusions_NNS of_IN Rossig_NNP et_CC al_NN ._. in_IN
          endothelialcells_NNS ._. They_PRP reported_VBD levels_NNS of_IN apoptotic_JJ cells_NNS
          for_IN control_NN andNYHA_NN III-IV_NNP hearts_NNS that_WDT were_VBD similar_JJ to_TO
          our_PRP$ observations_NNS [_NN 35_CD ]_NN ._. We_PRP similarly_RB believe_VBP that_IN the_DT
          suppressionof_NN apoptosis_NNS by_IN carvedilol_NN is_VBZ likely_JJ due_NN to_TO
          its_PRP$ antioxidative_JJ propertiesrather_NN than_IN the_DT β-blocking_JJ
          effects_NNS [_NN 35_CD ]_NN ._. Webase_NNP this_DT on_IN our_PRP$ observation_NN that_IN a_DT
          similar_JJ reduction_NN in_IN the_DT incidenceof_NN apoptosis_NNS was_VBD seen_VBN
          at_IN both_DT a_DT non-pharmacological_JJ (_( no_DT effect_NN onheart_NN rate_NN or_CC
          blood_NN pressure_NN )_) as_RB well_RB as_IN a_DT pharmacological_JJ doseof_NN
          carvedilol_NN ._. In_IN a_DT canine_JJ model_NN of_IN chronic_JJ heart_NN failure_NN
          producedby_NN multiple_JJ sequential_NN intracoronary_JJ
          embolizations_NNS ,_, metprolol_NN ,_, a_DT β_NN 
          1_CD selectiveblocker_NN ,_, reduced_VBD the_DT
          incidence_NN of_IN apoptosis_NNS supporting_VBG our_PRP$
          experimentalobservations_NNS with_IN carvedilol_NN [_NN 36_CD ]_NN ._. The_DT
          incidence_NN of_IN apoptosis_NNS was_VBD 5_CD ._. 32_CD ±_NN 0_CD ._. 77_CD in_IN heart_NN failure_NN
          animalsthat_NN were_VBD not_RB treated_VBN which_WDT is_VBZ similar_JJ to_TO our_PRP$
          findings_NNS of_IN 5_CD ._. 64_CD ±_NN 0_CD ._. 49_CD in_IN hearts_NNS from_IN untreated_JJ animals_NNS
          with_IN heart_NN failure_NN ._. Recently_RB ,_, Li_NNP et_CC al_NN ._. have_VBP demonstrated_VBN
          that_IN spontaneously_RB hypertensive_JJ rats_NNS (_( SHR_NNP )_) with_IN symptoms_NNS
          of_IN heart_NN failure_NN had_VBD significantly_RB higher_JJR levels_NNS
          ofapoptotic_JJ myocytes_NNS than_IN control_NN myocytes_NNS [_NN 37_CD ]_NN ._. When_WRB
          treated_VBN with_IN an_DT angiotensin-converting_JJ enzyme_NN inhibitor_NN ,_,
          thenumber_NN of_IN apoptotic_JJ cells_NNS in_IN the_DT SHR_NNP with_IN symptoms_NNS of_IN
          heart_NN failurewas_NNS dramatically_RB reduced_VBN to_TO control_VB levels_NNS ;_:
          controls_NNS were_VBD SHR_NNP withoutsymptoms_NNS of_IN heart_NN failure_NN [_NN 37_CD ]_NN
          ._. Kajstura_NNP et_CC al_NN ._. have_VBP also_RB reported_VBN that_DT angiotensin_NN II_NNP
          increased_VBD the_DT percentageof_NN apoptotic_JJ cells_NNS in_IN isolated_VBN
          adult_NN rat_NN ventricular_NN myocytes_NNS ,_, andthis_NNS effect_NN was_VBD
          mediated_JJ by_IN AT-_NNP 1_CD receptors_NNS [_NN 38_CD ]_NN ._. Although_IN ventricular_NN
          function_NN was_VBD not_RB assessed_VBN in_IN these_DT studies_NNS ,_, the_DT
          observations_NNS raise_VBP the_DT possibility_NN that_IN ,_, like_IN our_PRP$
          findings_NNS withcarvedilol_NN ,_, the_DT beneficial_JJ effect_NN of_IN
          ACE-inhibitors_NNP or_CC AT-_NNP 1_CD receptorblockers_NNS in_IN heart_NN failure_NN
          may_MD in_IN part_VB be_VB attributed_VBN to_TO an_DT inhibitionof_NN myocyte_NN
          apoptosis_NNS with_IN a_DT resultant_JJ improvement_NN in_IN 
          in_IN vivo_NN cardiacfunction_NN ,_, a_DT concept_NN
          that_WDT needs_VBZ further_JJ study_NN ._.
          The_DT data_NNS presented_VBN suggest_VBP that_DT attenuation_NN of_IN
          apoptosis_NNS mayunderlie_NN the_DT beneficial_JJ effect_NN of_IN β-blockade_JJ
          on_IN ventricular_NN function_NN ,_, and_CC that_IN the_DT inhibition_NN of_IN
          apoptosis_NNS can_MD possibly_RB lead_VB to_TO improvementin_NN ventricular_NN
          function_NN ._. This_DT represents_VBZ a_DT novel_NN mechanism_NN to_TO slowthe_NN
          progressive_JJ deterioration_NN of_IN myocardial_NN function_NN that_WDT can_MD
          occurin_NN patients_NNS with_IN cardiac_JJ failure_NN ._. Because_IN reactive_JJ
          oxygen_NN radicalsplay_NN a_DT role_NN in_IN inducing_VBG cell_NN apoptosis_NNS [_NN
          39_CD ]_NN andthe_NN potent_JJ antioxidant_NN property_NN of_IN carvedilol_NN [_NN
          12_CD ]_NN ,_, we_PRP speculate_VBP that_IN the_DT beneficial_JJ effectsattributed_JJ
          to_TO carvedilol_NN (_( i_NNP ._. e_SYM ._. inhibition_NN of_IN apoptosis_NNS and_CC
          improvementof_NN LV_NNP function_NN )_) are_VBP mediated_JJ ,_, in_IN part_NN ,_, by_IN its_PRP$
          prevention_NN of_IN oxygen-derived_JJ freeradical_JJ damage_NN [_NN 35_CD 40_CD ]_NN
          ._. Our_PRP$ data_NNS supportsthis_NNS idea_NN ._.
        
        
          Therapeutic_NNP Significance_NN
          With_IN the_DT clear_JJ demonstration_NN that_IN cardiac_JJ myocyte_NN
          apoptosis_NNS ispresent_NN in_IN our_PRP$ heart_NN failure_NN model_NN strategies_NNS
          for_IN prevention_NN ofapoptosis_NNS can_MD be_VB tested_VBN ._. The_DT clinical_JJ
          consensus_NN has_VBZ been_VBN that_IN higherdoses_NNS of_IN β-blockade_JJ should_MD
          incur_VB more_JJR benefits_NNS on_IN ventricular_NN remodeling_NN ._. However_RB ,_,
          our_PRP$ studies_NNS demonstrated_VBD similar_JJ benefits_NNS at_IN a_DT
          therapeuticand_NN sub-therapeutic_JJ dose_NN ._. In_IN light_NN of_IN the_DT
          beneficial_JJ effect_NN of_IN carvedilolon_NN the_DT progression_NN of_IN
          heart_NN failure_NN ,_, and_CC its_PRP$ unique_JJ multi-actionsthat_JJ are_VBP not_RB
          shared_VBN by_IN any_DT other_JJ β-blocking_JJ drug_NN or_CC by_IN any_DT otheragent_NN
          currently_RB used_VBD in_IN the_DT treatment_NN of_IN heart_NN failure_NN ,_, our_PRP$
          findingsrepresent_NN an_DT important_JJ new_JJ mechanism_NN of_IN improved_VBN
          cardiac_JJ function_NN ._.
          The_DT development_NN of_IN animal_NN models_NNS of_IN heart_NN failure_NN in_IN
          which_WDT apoptosisis_NNS an_DT important_JJ feature_NN will_MD allow_VB the_DT
          modulation_NN of_IN cell_NN deathpathways_NNS through_IN targeted_VBN
          interventions_NNS ._. Understanding_NNP the_DT roleof_NN specific_JJ
          signaling_VBG pathways_NNS in_IN cardiac_JJ myocyte_NN apoptosis_NNS
          anddeveloping_VBG strategies_NNS to_TO manipulate_VB these_DT
          intracellular_NN pathwaysmay_NN provide_VB in_IN the_DT near_JJ future_JJ
          novel_NN therapeutic_JJ approaches_NNS forthe_NN management_NN of_IN heart_NN
          failure_NN ._.
        
      
      
        Conclusions_NNP
        In_IN conclusion_NN ,_, our_PRP$ model_NN of_IN heart_NN failure_NN ,_, which_WDT shows_VBZ a_DT
        highlevel_NN of_IN congruence_NN with_IN the_DT human_JJ condition_NN ,_, has_VBZ been_VBN
        shown_VBN tohave_NN a_DT high_JJ level_NN of_IN apoptosis_NNS that_IN corresponds_NNS
        with_IN cardiac_JJ failure_NN ._. Carvedilol_NNP ,_, a_DT non-selective_JJ β-blocker_JJ
        with_IN α-blocking_JJ propertiesas_NNS well_RB as_IN antioxidant_NN
        properties_NNS ,_, significantly_RB reduced_VBD the_DT incidenceof_NN
        programmed_VBN cell_NN death_NN while_IN improving_VBG cardiac_JJ function_NN ._.
        Thiseffect_NNP was_VBD independent_JJ of_IN heart_NN rate_NN lowering_VBG effects_NNS ,_,
        i_NNP ._. e_SYM ._. β-blockade_JJ ._. The_DT beneficial_JJ effects_NNS of_IN carvedilol_NN can_MD
        therefore_RB be_VB obtained_VBN withsubtherapeutic_JJ doses_NNS ._. This_DT is_VBZ a_DT
        novel_NN observation_NN and_CC importantin_NN treating_VBG patients_NNS who_WP may_MD
        not_RB tolerate_VB higher_JJR doses_NNS (_( heart_NN rateand_NN blood_NN pressure_NN
        lowering_VBG )_) of_IN carvedilol_NN ._. The_DT apoptotic_JJ processis_NNS linked_VBN to_TO
        the_DT development_NN and_CC progression_NN of_IN heart_NN failure_NN aswell_NN as_IN
        the_DT improvement_NN in_IN cardiac_JJ function_NN seen_VBN with_IN
        β-blockade_JJ ._.
      
      
        Methods_NNP
        
          Experimental_NNP Design_NNP
          One_CD day-old_JJ broad-breasted_JJ white_JJ turkey_NN poults_NNS ,_,
          obtained_VBN froma_NN commercial_JJ breeder_NN ,_, were_VBD wing-banded_JJ for_IN
          easy_JJ identification_NN ._. At_IN seven_CD days_NNS of_IN age_NN ,_, they_PRP were_VBD
          weighed_VBN and_CC randomly_RB divided_VBN intotwo_NN groups_NNS using_VBG a_DT
          random_JJ number_NN generator_NN ._. The_DT control_NN group_NN (_( n_NN =_SYM 34_CD )_) was_VBD
          maintained_VBN on_IN a_DT normal_JJ ration_NN ,_, free_JJ from_IN any_DT
          additives_NNS ,_, and_CC the_DT experimental_JJ group_NN (_( n_NN =_SYM 91_CD )_) was_VBD fed_VBN 700_CD
          parts_NNS per_IN millionfurazolidone_NN (_( Fz_NNP )_) for_IN three_CD weeks_NNS ._.
          Furazolidone_NNP was_VBD stopped_VBN afterday_NN twenty-eight_JJ and_CC the_DT
          animals_NNS were_VBD randomized_JJ into_IN three_CD groups_NNS :_: one_CD group_NN did_VBD
          not_RB receive_VB carvedilol_NN treatment_NN ,_, DCM_NNP 
          0_CD (_( n_NN =_SYM 52_CD )_) ,_, whereas_IN the_DT other_JJ two_CD
          groups_NNS ,_, DCM_NNP 
          1_CD (_( n_NN =_SYM 19_CD )_) andDCM_NN 
          20_CD (_( n_NN =_SYM 20_CD )_) ,_, were_VBD treated_VBN with_IN
          carvedilol_NN in_IN the_DT samedosages_NNS as_IN respective_JJ aged-matched_JJ
          control_NN animals_NNS (_( see_VB following_VBG )_) ._. Similarly_RB ,_, age_NN matched_VBD
          control_NN animals_NNS were_VBD randomized_JJ into_IN threegroups_NNS :_: one_CD
          group_NN received_VBD no_DT pharmacological_JJ agent_NN (_( Con_NN 
          0_CD ._. n_NN =_SYM 13_CD )_) ,_, whereas_IN the_DT other_JJ two_CD
          groups_NNS received_VBD different_JJ dosagesof_NN carvedilol_NN ,_, 1_CD mg_NN /_NN kg_NN
          (_( Con_NN 
          1_CD n_NN =_SYM 11_CD )_) or_CC 20_CD mg_NN /_NN kg_NN bodyweight_NN (_( Con_NN 
          20_CD n_NN =_SYM 10_CD )_) ._. The_DT lower_JJR dose_NN of_IN
          carvedilol_NN didnot_NN lower_JJR heart_NN rate_NN or_CC blood_NN pressure_NN ._.
          However_RB ,_, the_DT higher_JJR doseof_NN carvedilol_NN resulted_VBD in_IN a_DT
          significant_JJ reduction_NN in_IN heart_NN rate_NN (_( 15_CD %_NN )_) and_CC blood_NN
          pressure_NN (_( 9_CD %_NN )_) for_IN up_IN to_TO eight_CD hours_NNS ._. We_PRP performeddose_NN
          range_NN studies_NNS using_VBG nine_CD concentrations_NNS of_IN carvedilol_NN
          (_( datanot_NN shown_VBN )_) ._. At_IN the_DT time_NN of_IN euthanasia_NN ,_, body_NN weights_NNS ,_,
          heart_NN weights_NNS (_( after_IN removal_NN of_IN the_DT atria_NN )_) ,_, and_CC LV_NNP volumes_NNS
          were_VBD obtained_VBN on_IN allexperimental_NN animals_NNS ._.
        
        
          Echocardiographic_NNP Measurements_NNP
          Echocardiographic_NNP views_NNS were_VBD obtained_VBN using_VBG a_DT 7_CD ._. 5_CD MHz_NNP
          transduceron_NN unsedated_JJ and_CC quietly_RB resting_VBG animals_NNS ._.
          Several_JJ cardiac_JJ cycleswere_NN recorded_VBN on_IN a_DT videotape_NN and_CC
          the_DT two_CD dimensional_NN images_NNS subsequentlyplayed_JJ back_RB for_IN
          analysis_NN ._. Diastolic_NNP left_VBD ventricular_NN internal_JJ dimension_NN
          (_( LVIDd_NNP )_) and_CC systolic_JJ left_JJ ventricular_NN internal_JJ dimension_NN
          (_( LVIDs_NNP )_) were_VBD alsomeasured_JJ and_CC used_VBN to_TO determine_VB the_DT
          fractional_JJ shortening_NN ._. Fractionalshortening_NNP (_( %_NN )_) of_IN the_DT
          left_NN ventricle_NN was_VBD calculated_VBN as_IN (_( LVIDd_NNP -_: LVIDs_NNP /_NN LVIDd_NNP )_) ×_NN
          100_CD ._.
        
        
          TUNEL_NNP
          Randomly_NNP selected_VBD hearts_NNS from_IN control_NN and_CC
          cardiomyopathic_JJ turkeypoults_NNS were_VBD rapidly_RB removed_VBN ,_,
          flushed_JJ with_IN PBS_NNP and_CC infused_VBN with_IN atissue_NN embedding_VBG
          medium_NN (_( Tissue-_NNP Tek_NNP ,_, OCT_NNP Compound_NN ,_, Miles_NNP Inc_NNP ._. ,_, Elkhart_NNP ,_, IN_IN )_)
          and_CC frozen_VBN in_IN liquid_JJ nitrogen_NN ._. Serial_JJ 7_CD μm_NN cross-sections_JJ
          from_IN heartblocks_NNS were_VBD cut_VBN and_CC fixed_VBN to_TO coated_JJ slides_NNS ._.
          Frozen_NNP heart_NN sectionswere_NN fixed_VBN in_IN 10_CD %_NN neutral_JJ formalin_NN
          (_( 4_CD %_NN formaldehyde_NN )_) for_IN 10_CD minutesat_NN room_NN temperature_NN and_CC
          post-fixed_JJ in_IN Methanol_NNP /_NN Acetone_NNP (_( 1_CD :_: 1_LS )_) for_IN 10_CD minutes_NNS at_IN
          -_: 20_CD °_NN C_NNP ._. Detection_NNP of_IN apoptotic_JJ cardiac_JJ myocytes_NNS was_VBD
          achievedby_NN direct_JJ immunofluorescence_NN detection_NN of_IN
          digoxigenin-labeled_JJ genomicDNA_NN using_VBG the_DT ApopTag_NNP Plus_NNP in_IN
          Situ_NNP apoptosis_NNS detection_NN kit_NN -_: Fluorescein_NNP (_( Intergen_NNP ,_,
          Purchase_NNP ,_, NY_NNP )_) ._. This_DT method_NN used_VBD the_DT TUNEL_NNP techniqueto_NN
          stain_VB DNA_NNP fragments_NNS in_IN nuclei_NN of_IN apoptotic_JJ cells_NNS ._. Tissue_NNP
          sectionswere_NN then_RB counter-stained_JJ with_IN Hoechst_NNP 33258_CD
          stain_VB (_( 1_CD μg_NN /_NN ml_NN )_) (_( Sigma_NNP )_) ,_, and_CC viewed_VBD with_IN an_DT
          epifluorescence_NN microscope_NN (_( Zeiss_NNP Axiophot_NNP )_) equippedwith_NN
          filter_NN sets_NNS for_IN fluorescein_NN and_CC Hoechst_NNP staining_VBG ._. To_TO
          quantify_VB apoptosis_NNS ,_, four_CD to_TO five_CD randomly_RB selected_VBN
          microscopic_JJ fields_NNS per_IN section_NN wereexamined_JJ ._. The_DT
          percentage_NN of_IN apoptotic_JJ cells_NNS was_VBD determined_VBN by_IN
          countingthe_NN total_JJ number_NN of_IN nuclei_NN and_CC TUNEL_NNP positive_JJ
          nuclei_NN (_( apoptoticmyocytes_NNS )_) ._. Samples_NNP were_VBD numbered_VBN to_TO
          conceal_VB the_DT identity_NN of_IN differentgroups_NNS during_IN counting_VBG ._.
          Sections_NNP of_IN interest_NN were_VBD photographed_VBN usinga_NN
          microscope-integrated_JJ 35_CD -_: mm_NN camera_NN ._.
        
        
          Statistical_NNP Analysis_NNP
          Data_NNP given_VBN in_IN the_DT text_NN are_VBP means_VBZ ±_NN SD_NNP ._. The_DT difference_NN
          betweenthe_NN means_VBZ was_VBD evaluated_VBN using_VBG student_NN 's_POS 
          t_NN test_NN ._. P_NN <_NN 0_CD ._. 05_CD was_VBD considered_VBN
          significant_JJ ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        CCO_NNP drafted_VBD and_CC edited_JJ the_DT manuscript_NN ._. AAD_NNP carried_VBD out_IN
        creationof_NN the_DT animal_NN model_NN ._. ECHOs_NNP and_CC the_DT
        echocardiographic_JJ measurementswere_NN analyzed_VBN by_IN NL_NNP and_CC JKG_NNP ._.
        DL_NNP ,_, KS_NNP and_CC GJ_NNP carried_VBD out_RP the_DT TUNELassays_NNP ._. CCO_NNP ,_, CPM_NNP ,_, RJH_NNP
        and_CC JKG_NNP participated_VBD in_IN the_DT design_NN of_IN thestudy_NN ._. CCO_NNP and_CC JKG_NNP
        performed_VBD the_DT statistical_JJ analysis_NN ,_, and_CC datainterpretation_NN ._.
        MXL_NNP performed_VBD figure_NN generation_NN and_CC animal_NN dosing_VBG ._. RJH_NNP and_CC
        JKG_NNP conceived_VBD of_IN the_DT study_NN ,_, and_CC participated_VBD in_IN its_PRP$
        designand_NN coordination_NN ._. All_DT authors_NNS read_VBP and_CC approved_VBD the_DT
        final_JJ manuscript_NN ._.
      
    
  
